Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemi...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

InvestorNOR Sep. 15 at 3:05 PM

$CMMB S-4 going public any day now. SEC have for sure commented and reviewed the confidental S-4 by now. If they found no issues, we can move on to voting very soon

1 · Reply

DLTT4489 Sep. 15 at 2:49 AM

$CMMB idiots, it's just the beginning.

0 · Reply

shreyvakil Sep. 14 at 7:17 PM

$CMMB got 10k more here on this drop here! 🙏

1 · Reply

InvestorNOR Sep. 14 at 3:22 PM

$CMMB 420 shares dumped it from $2.52 to $2.47. So a total of 720 shares sell volume dumped it 4%

0 · Reply

InvestorNOR Sep. 14 at 2:35 PM

$CMMB a simple 300 volume sell order cause price to go down from 2.58 to 2.52 😅

0 · Reply

Zdxss1 Sep. 12 at 4:15 AM

$CMMB Management continues, for the fourth consecutive time, to publicly signal that the PSC program is available for partnership. This means the possibility of a better offer is still on the table, which is a positive sign

0 · Reply

DLTT4489 Sep. 11 at 10:41 PM

$CMMB did you buy at 3 again 😅😅

0 · Reply

DLTT4489 Sep. 11 at 5:13 PM

$CMMB they trapped poor people again, won't be surprised if closes red

0 · Reply

InvestorNOR Sep. 11 at 4:40 PM

$CMMB

1 · Reply

InvestorNOR Sep. 11 at 4:28 PM

$CMMB Grok estimates the PrismRA to be $100M over 5 years. So about $20M per year. Then there is additional revenue from SPECTRA and Immunology, which could be from $5-10M. So an estimate should be roughly $25-30M per year in revenue. Plus $30M cash. Plus PSC partnership catalyst on top of that. Thats the story with Scipher going forward. The PR today contained a lot of information that goes on a S-4, so I assume they could make it public any day now.

0 · Reply

Chemomab Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Aug 31, 2026, 8:00 AM EDT - 15 days ago

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Aug 26, 2026, 8:00 AM EDT - 20 days ago

Chemomab Therapeutics Slides: Investor presentation

Aug 19, 2026, 12:30 PM EDT - 27 days ago

Chemomab Therapeutics Earnings release: Q2 2026

Aug 19, 2026, 8:26 AM EDT - 27 days ago

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Chemomab Therapeutics Transcript: M&A announcement

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Chemomab Therapeutics Press release: M&A announcement

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Chemomab Therapeutics Slides: M&A announcement

2026-07-08T11:46:10.000Z - 2 months ago

Chemomab Therapeutics, Scipher Medicine announce merger agreement

Jul 8, 2026, 7:35 AM EDT - 2 months ago

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

May 14, 2026, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics Earnings release: Q1 2026

2026-03-19T12:11:46.000Z - 6 months ago

Chemomab Therapeutics sees cash runway through 1Q27

2026-03-19T12:05:34.000Z - 6 months ago

Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year

Mar 19, 2026, 8:00 AM EDT - 6 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Mar 19, 2026, 8:00 AM EDT - 6 months ago

Chemomab Therapeutics Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 6 months ago

Chemomab Therapeutics Earnings release: Q4 2025

Mar 1, 2026, 6:00 AM EST - 6 months ago

Chemomab Therapeutics Slides: Corporate presentation

Feb 26, 2026, 8:00 AM EST - 6 months ago

Chemomab Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 7 months ago

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

2025-12-02T13:15:59.000Z - 9 months ago

Chemomab Therapeutics announces results of its Phase 2 SPRING trial

Dec 2, 2025, 8:00 AM EST - 9 months ago

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Nov 24, 2025, 8:00 AM EST - 9 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 21, 2025, 7:00 AM EST - 9 months ago

Chemomab Therapeutics Earnings release: Q3 2025

2025-11-20T13:05:27.000Z - 9 months ago

Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year

Nov 20, 2025, 8:00 AM EST - 9 months ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-06T13:47:57.000Z - 10 months ago

Chemomab announces presentations at AASLD 2025 on nebokitug data

Nov 6, 2025, 8:00 AM EST - 10 months ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

2025-09-12T16:55:11.000Z - 1 year ago

Chemomab Therapeutics management to meet with Maxim

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-08-27T16:21:06.000Z - 1 year ago

Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer

2025-08-25T23:50:06.000Z - 1 year ago

Chemomab Therapeutics Ltd – ADR trading halted, news pending

Aug 21, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

2025-08-14T12:11:23.000Z - 1 year ago

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:00 PM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q2 2025

2025-07-31T17:55:26.000Z - 1 year ago

Chemomab Therapeutics management to meet with Maxim

2025-06-30T14:35:01.000Z - 1 year ago

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

2025-06-11T12:05:42.000Z - 1 year ago

Chemomab obtained feedback from two recent FDA meetings on nebokitug

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

2025-06-03T12:05:13.000Z - 1 year ago

Chemomab announces nebokitug awarded new patent protection in China, Russia

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

2025-05-16T11:36:15.000Z - 1 year ago

Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer

2025-05-15T12:16:43.000Z - 1 year ago

Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q1 2025

2025-05-05T12:11:50.000Z - 1 year ago

Chemomab Therapeutics announces presentation of Phase 2 data of CM-101

May 5, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

2025-04-28T12:31:07.000Z - 1 year ago

Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Medical and Clinical Appointments

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 6, 2025, 8:00 AM EST - 1 year ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 3, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Annual report: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 11, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Nov 19, 2024, 7:00 AM EST - 1 year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q3 2024

Aug 23, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Registration statement: Registration Filing

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Press release: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Slides: Study Result

Jul 25, 2024, 7:38 AM EDT - 2 years ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 10, 2024, 10:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: KOL Event

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 2 years ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Annual report: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 2 years ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

InvestorNOR Sep. 15 at 3:05 PM

$CMMB S-4 going public any day now. SEC have for sure commented and reviewed the confidental S-4 by now. If they found no issues, we can move on to voting very soon

1 · Reply

DLTT4489 Sep. 15 at 2:49 AM

$CMMB idiots, it's just the beginning.

0 · Reply

shreyvakil Sep. 14 at 7:17 PM

$CMMB got 10k more here on this drop here! 🙏

1 · Reply

InvestorNOR Sep. 14 at 3:22 PM

$CMMB 420 shares dumped it from $2.52 to $2.47. So a total of 720 shares sell volume dumped it 4%

0 · Reply

InvestorNOR Sep. 14 at 2:35 PM

$CMMB a simple 300 volume sell order cause price to go down from 2.58 to 2.52 😅

0 · Reply

Zdxss1 Sep. 12 at 4:15 AM

0 · Reply

DLTT4489 Sep. 11 at 10:41 PM

$CMMB did you buy at 3 again 😅😅

0 · Reply

DLTT4489 Sep. 11 at 5:13 PM

$CMMB they trapped poor people again, won't be surprised if closes red

0 · Reply

InvestorNOR Sep. 11 at 4:40 PM

$CMMB

1 · Reply

InvestorNOR Sep. 11 at 4:28 PM

0 · Reply

DLTT4489 Sep. 11 at 3:03 PM

$CMMB another short day 🤪🤪

0 · Reply

Stockhunter008 Sep. 11 at 2:39 PM

looks like the $CMMB Scipher Merger is a go!

0 · Reply

Snptrader Sep. 11 at 2:01 PM

$CMMB Any idea what a PrismRA kit costs?

1 · Reply

cpatel2000 Sep. 11 at 1:24 PM

$CMMB NEW CONFIRMED FACTS 50,000 PrismRA tests — updated from 45,000 mentioned earlier. Growing faster than previously disclosed. 30+ RA clinical sites from the PREDICT study — Scipher has an existing clinical network ready to enroll Phase 2 patients immediately. IND submission H2 2026 — they are submitting the RA IND this year, before merger close. This is significant — it demonstrates the RA program is real and advancing independently. THE PSC LANGUAGE — FOURTH CONSECUTIVE STATEMENT Adi Mor said: "it is important to emphasize that PSC, a potential lethal disease with no FDA-approved drugs, remains an important opportunity for nebokitug, potentially via partnering." The Wainwright presentation confirms the deal is proceeding, the RA thesis is credible, and management continues to publicly signal PSC partnership availability for the fourth consecutive time

1 · Reply

InvestorNOR Sep. 11 at 12:16 PM

$CMMB $CMMB A lot of new details today about neboktiug, Chemomab`s merger with Scipher, and about the upcoming RA trial https://uk.investing.com/news/stock-market-news/chemomab-at-hc-wainwright-conference-merger-sets-ra-push-93CH-4866231

0 · Reply

Snptrader Sep. 11 at 11:30 AM

$CMMB short interest down to 102K (35k avail at 112% borrow rate) Anyone listen to the HC Wainwright presentation?? Thoughts?

0 · Reply

shreyvakil Sep. 11 at 10:44 AM

$CMMB 44k sell ask at 2.78, someone does not want to go up! 🤔

0 · Reply

InvestorNOR Sep. 10 at 4:38 PM

$CMMB Something is coming soon and building up here. I can feel it in the air. Perfect storm

0 · Reply

shreyvakil Sep. 10 at 2:35 PM

$CMMB short volume almost 70% high yesterday! Dont sell here, let them cover way higher

0 · Reply

grumpygoose Sep. 10 at 1:16 AM

$CMMB

0 · Reply

Biotech_Pharma_Investor Sep. 9 at 8:42 PM

$CMMB Another 12.5% holder supporting the merger (13D today)

1 · Reply

InvestorNOR Sep. 9 at 2:05 PM

$CMMB Thanks buddy 🍻

2 · Reply

Market Cap	17.75M
Revenue (ttm)	0.00
Net Income (ttm)	-9.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	50,800
Avg Vol	147,464
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	17%
Beta	0.76
Analysts	Sell
Price Target	$5.00